Cardinal Health will manufacture and distribute Amyvid (florbetapir F18) the new diagnostic imaging agent from Eli Lilly and Company that...
Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced that Amyvid (Florbetapir F 18...
The FDA has approved Amyvid (florbetapir F18)from Eli Lilly and its subsidiary Avid Radiopharmaceuticals. Amyvid is a radioactive diagnostic agent...
The Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Amyvid (florbetapir 18F) from Eli Lilly,...
Results of a new study to assess the value of Amyvid (florbetapir F18) PET, from Cardinal Health, in detecting brain...
The FDA has on 25 October 2013 approved Vizamyl (flutemetamol F 18 injection) from GE HealthCare Inc, a radioactive diagnostic...
Tauvid a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD).